Search

Your search keyword '"Drenth, Joost P H"' showing total 1,165 results
Start Over Author "Drenth, Joost P H"
1,165 results on '"Drenth, Joost P H"'

1. Preventive Measures and Risk Factors for Post-ERCP Pancreatitis: A Systematic Review and Individual Patient Data Meta-Analysis

Author

Sperna Weiland, Christina J., Akshintala, Venkata S., Singh, Anmol, Buxbaum, James, Choi, Jun-Ho, Elmunzer, Badih J., Fogel, Evan S., Lai, Jian-Han, Levenick, John M., Gardner, Timothy B., Lua, Guan W., Luo, Hui, de Jong, Mike, Mok, Shaffer R. S., Phillip, Veit, Singh, Vikesh, Siersema, Peter D., Drenth, Joost P. H., and van Geenen, Erwin J. M.

Published
2024
Full Text
View/download PDF

2. Detection of polyreactive immunoglobulin G facilitates diagnosis in children with autoimmune hepatitis

Author

Engel, Bastian, Diestelhorst, Jana, Hupa-Breier, Katharina Luise, Kirchner, Theresa, Henjes, Nicole, Loges, Stephanie, Yuksel, Muhammed, Janczyk, Wojciech, Lalanne, Claudine, Zachou, Kalliopi, Oo, Ye H., Gournay, Jérôme, Pape, Simon, Drenth, Joost P. H., Renand, Amédée, Dalekos, George N., Muratori, Luigi, Socha, Piotr, Ma, Yun, Arikan, Cigdem, Baumann, Ulrich, Manns, Michael P., Wedemeyer, Heiner, Junge, Norman, Jaeckel, Elmar, and Taubert, Richard

Published
2024
Full Text
View/download PDF

4. Recurrences of advanced sessile and lateral spreading colorectal adenoma after endoscopic mucosal resection (EMR) thermal ablation versus no adjuvant therapy (RESPECT): a protocol of an international randomized controlled trial

Author

Kemper, Gijs, Gerges, Christian, Schoon, Erik J., Schreuder, Ramon-Michel, Schrauwen, Ruud R. W., Epping, Ludger S. M., Beyna, Torsten, Drenth, Joost P. H., Gündug, Ufuk, Siersema, Peter D., and van Geenen, Erwin J. M.

Published
2024
Full Text
View/download PDF

5. Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial

Author

Stoelinga, Anna E. C., Tushuizen, Maarten E., van den Hout, Wilbert B., Girondo, Mar D. M. Rodriguez, de Vries, Elsemieke S., Levens, Amar D., Moes, Dirk-Jan A. R., Gevers, Tom J. G., van der Meer, Suzanne, Brouwer, Hans T., de Jonge, Hendrik J. M., de Boer, Ynte S., Beuers, Ulrich H. W., van der Meer, Adriaan J., van den Berg, Aad P., Guichelaar, Maureen M. J., Drenth, Joost P. H., and van Hoek, Bart

Published
2024
Full Text
View/download PDF

6. Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework

Author

Duijzer, Renée, Bernts, Lucas H P, Geerts, Anja, van Hoek, Bart, Coenraad, Minneke J, Rovers, Chantal, Alvaro, Domenico, Kuijper, Ed J, Nevens, Frederik, Halbritter, Jan, Colmenero, Jordi, Kupcinskas, Juozas, Salih, Mahdi, Hogan, Marie C, Ronot, Maxime, Vilgrain, Valerie, Hanemaaijer, Nicolien M, Kamath, Patrick S, Strnad, Pavel, Taubert, Richard, Gansevoort, Ron T, Torra, Roser, Nadalin, Silvio, Suwabe, Tatsuya, Gevers, Tom J G, Cardinale, Vincenzo, Drenth, Joost P H, and Lantinga, Marten A

Published
2024
Full Text
View/download PDF

13. Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial

Author

Snijders, Romée J. A. L. M., Stoelinga, Anna E. C., Gevers, Tom J. G., Pape, Simon, Biewenga, Maaike, Verdonk, Robert C., de Jonge, Hendrik J. M., Vrolijk, Jan Maarten, Bakker, Sjoerd F., Vanwolleghem, Thomas, de Boer, Ynto S., Pronk, Martine A. M. C. Baven, Beuers, Ulrich H. W., van der Meer, Adriaan J., van Gerven, Nicole M. F., Sijtsma, Marijn G. M., Verwer, Bart J., Gisbertz, Ingrid A. M., Bartelink, Maartje, van den Brand, Floris F., Sebib Korkmaz, Kerem, van den Berg, Aad P., Guichelaar, Maureen M. J., Soufidi, Khalida, Levens, Amar D., van Hoek, Bart, and Drenth, Joost P. H.

Published
2022
Full Text
View/download PDF

14. The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)

Author

de-Madaria, Enrique, Mira, José J, Carrillo, Irene, Afif, Waqqas, Ang, Daphne, Antelo, Marina, Bollipo, Steven, Castells, Antoni, Chahal, Prabhleen, Heinrich, Henriette, Law, Joanna K, van Leerdam, Monique E, Lens, Sabela, Pannala, Rahul, Park, San Hyoung, Rabiee, Atoosa, Savarino, Edoardo V, Singh, Vikesh K, Vargo, John, Charabaty, Aline, and Drenth, Joost P H

Published
2022
Full Text
View/download PDF

15. Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma.

Author

Stern, Louisa, Schmidt, Constantin, Kocheise, Lorenz, Joerg, Vincent, Casar, Christian, Walter, Aurélie, Drenth, Joost P. H., Papp, Maria, Gatselis, Nikolaos K., Zachou, Kalliopi, Pinter, Matthias, Scheiner, Bernhard, Vogel, Arndt, Kirstein, Martha M., Finkelmeier, Fabian, Waidmann, Oliver, Weinmann, Arndt, Milkiewicz, Piotr, Thorburn, Douglas, and Halliday, Neil

Abstract

Introduction and Objectives: Autoimmune liver diseases (AILD) are rare causes hepatocellular carcinoma (HCC), and data on the efficacy and tolerability of anti-tumor therapies are scarce. This pan-European study aimed to assess outcomes in AILD-HCC patients treated with tyrosine kinase inhibitors (TKIs) or transarterial chemoembolization (TACE) compared with patients with more common HCC etiologies, including viral, alcoholic or non-alcoholic fatty liver disease. Materials and Methods: 107 patients with HCC-AILD (AIH:55; PBC:52) treated at 13 European centres between 1996 and 2020 were included. 65 received TACE and 28 received TKI therapy. 43 (66 %) were female (median age 73 years) with HCC tumor stage BCLC A (34 %), B (46 %), C (9 %) or D (11 %). For each treatment type, propensity score matching was used to match AILD to non-AILD-HCC on a 1:1 basis, yielding in a final cohort of 130 TACE and 56 TKI patients for comparative analyses of median overall survival (mOS) and treatment tolerability. Results: HCC-AILD patients showed comparable mOS to controls for both TACE (19.5 vs. 22.1 months, p = 0.9) and TKI (15.4 vs. 15.1 months, p = 0.5). Adverse events were less frequent in AILD-HCC patients than controls (33 % % vs. 62 %, p = 0.003). For TKIs, there were no significant differences in adverse events (73% vs. 86%, p = 0.2) or interruption rates (44% vs. 36 %, p = 0.7). Conclusions: In summary, this study demonstrates comparable mOS for AILD-HCC patients undergoing local and systemic treatments, with better tolerability than HCC of other causes. TKIs remain important therapeutic options for AILD-HCC patients, particularly given their exclusion from recent immunotherapy trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis

Author

Goltstein, Lia C M J, Grooteman, Karina V, Rocco, Alba, Holleran, Grainne, Frago, Santiago, Salgueiro, Paulo S, Aparicio, Thomas, Scaglione, Giuseppe, Chetcuti Zammit, Stefania, Prados-Manzano, Raul, Benamouzig, Robert, Nardone, Gerardo, McNamara, Deirdre, Benallaoua, Mourad, Michopoulos, Spyridon, Sidhu, Reena, Kievit, Wietske, Drenth, Joost P H, and van Geenen, Erwin J M

Published
2021
Full Text
View/download PDF

17. Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis

Author

Akshintala, Venkata S, Sperna Weiland, Christina J, Bhullar, Furqan A, Kamal, Ayesha, Kanthasamy, Kavin, Kuo, Albert, Tomasetti, Cristian, Gurakar, Merve, Drenth, Joost P H, Yadav, Dhiraj, Elmunzer, B Joseph, Reddy, D Nageshwar, Goenka, Mahesh K, Kochhar, Rakesh, Kalloo, Anthony N, Khashab, Mouen A, van Geenen, Erwin J M, and Singh, Vikesh K

Published
2021
Full Text
View/download PDF

18. Aggressive fluid hydration plus non-steroidal anti-inflammatory drugs versus non-steroidal anti-inflammatory drugs alone for post-endoscopic retrograde cholangiopancreatography pancreatitis (FLUYT): a multicentre, open-label, randomised, controlled trial

Author

Sperna Weiland, Christina J, Smeets, Xavier J N M, Kievit, Wietske, Verdonk, Robert C, Poen, Alexander C, Bhalla, Abha, Venneman, Niels G, Witteman, Ben J M, da Costa, David W, van Eijck, Brechje C, Schwartz, Matthijs P, Römkens, Tessa E H, Vrolijk, Jan Maarten, Hadithi, Muhammed, Voorburg, Annet M C J, Baak, Lubbertus C, Thijs, Willem J, van Wanrooij, Roy L, Tan, Adriaan C I T L, Seerden, Tom C J, Keulemans, Yolande C A, de Wijkerslooth, Thomas R, van de Vrie, Wim, van der Schaar, Peter, van Dijk, Sven M, Hallensleben, Nora D L, Sperna Weiland, Ruud L, Timmerhuis, Hester C, Umans, Devica S, van Hooft, Jeanin E, van Goor, Harry, van Santvoort, Hjalmar C, Besselink, Marc G, Bruno, Marco J, Fockens, Paul, Drenth, Joost P H, and van Geenen, Erwin J M

Published
2021
Full Text
View/download PDF

20. Serum bile acids associate with liver volume in polycystic liver disease and decrease upon treatment with lanreotide.

Author

Dekker, Shosha E. I., Bierau, Jörgen, Giera, Martin, Blomberg, Niek, Drenth, Joost P. H., Mayboroda, Oleg A., de Fijter, Johan W., Soonawala, Darius, Gansevoort, Ron T., Meijer, Esther, Peters, Dorien J.M., Wetzels, Jack F., and Zietse, Robert

Subjects
BILE acids, POLYCYSTIC kidney disease, LIQUID chromatography-mass spectrometry, LIVER diseases
Abstract

Background: Polycystic liver disease (PLD) is a common extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). Bile acids may play a role in PLD pathogenesis. We performed a post‐hoc exploratory analysis of bile acids in ADPKD patients, who had participated in a trial on the effect of a somatostatin analogue. Our hypothesis was that serum bile acid levels increase in PLD, and that lanreotide, which reduces liver growth, may also reduce bile acid levels. Furthermore, in PLD, urinary excretion of bile acids might contribute to renal disease. Methods: With liquid chromatography‐mass spectrometry, 11 bile acids in serum and 6 in urine were quantified in 105 PLD ADPKD patients and 52 age‐, sex‐, mutation‐ and eGFR‐matched non‐PLD ADPKD patients. Sampling was done at baseline and after 120 weeks of either lanreotide or standard care. Results: Baseline serum levels of taurine‐ and glycine‐conjugated bile acids were higher in patients with larger livers. In PLD patients, multiple bile acids decreased upon treatment with lanreotide but remained stable in untreated subjects. Changes over time did not correlate with changes in liver volume. Urine bile acid levels did not change and did not correlate with renal disease progression. Conclusion: In ADPKD patients with PLD, baseline serum bile acids were associated with liver volume. Lanreotide reduced bile acid levels and has previously been shown to reduce liver volume. However, in this study, the decrease in bile acids was not associated with the change in liver volume. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Patients with Clinically Suspected Gallstone Disease: A More Selective Ultrasound May Improve Treatment Related Outcomes

Author

Thunnissen, Floris M., primary, Comes, Daan J., additional, Geenen, Remy W. F., additional, Riviere, Deniece, additional, Latenstein, Carmen S. S., additional, Lantinga, Marten A., additional, Schers, Henk J., additional, van Laarhoven, Cornelis J. H. M., additional, Drenth, Joost P. H., additional, Atsma, Femke, additional, and de Reuver, Philip R., additional

Published
2023
Full Text
View/download PDF

33. Socio‐economic factors associated with loss to follow‐up among individuals with HCV: A Dutch nationwide cross‐sectional study.

Author

van Dijk, Marleen, Boyd, Anders, Brakenhoff, Sylvia M., Isfordink, Cas J., van Zoest, Rosan A., Verhagen, Mark D., de Knegt, Robert J., Drenth, Joost P. H., van der Valk, Marc, van Wijngaarden, Peter, Douma, Renée A., Erkelens, Willemien G., Lammers, Adriana J. J., de Jonge, Hendrik J. M., Bus, Paul J., den Hollander, Jan G., Posthouwer, Dirk, Klemt‐Kropp, Michael, and Baak, Lubbertus C.

Subjects
SOCIOECONOMIC factors, INCOME, HEPATITIS C virus, CROSS-sectional method, DEATH rate
Abstract

Background and Aims: The path to hepatitis C virus (HCV) elimination is complicated by individuals who become lost to follow‐up (LTFU) during care, particularly before receiving effective HCV treatment. We aimed to determine factors contributing to LTFU and whether LTFU is associated with mortality. Methods: In this secondary analysis, we constructed a database including individuals with HCV who were either LTFU (data from the nationwide HCV retrieval project, CELINE) or treated with directly acting antivirals (DAA) (data from Statistics Netherlands) between 2012 and 2019. This database was linked to mortality data from Statistics Netherlands. Determinants associated with being LTFU versus DAA‐treated were assessed using logistic regression, and mortality rates were compared between groups using exponential survival models. These analyses were additionally stratified on calendar periods: 2012–2014, 2015–2017 and 2018–2019. Results: About 254 individuals, LTFU and 5547 DAA‐treated were included. Being institutionalized (OR = 5.02, 95% confidence interval (CI) = 3.29–7.65), household income below the social minimum (OR = 1.96, 95% CI = 1.25–3.06), receiving benefits (OR = 1.74, 95% CI = 1.20–2.52) and psychiatric comorbidity (OR = 1.51, 95% CI = 1.09–2.10) were associated with LTFU. Mortality rates were significantly higher in individuals LTFU compared to those DAA‐treated (2.99 vs. 1.15/100 person‐years (PY), p <.0001), while in those DAA‐treated, mortality rates slowly increased between 2012–2014 (.22/100PY) and 2018–2019 (2.25/100PY). Conclusion: In the Netherlands, individuals who are incarcerated/institutionalized, with low household income, or with psychiatric comorbidities are prone to being LTFU, which is associated with higher mortality. HCV care needs to be adapted for these vulnerable individuals. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Suspected common bile duct stones:reduction of unnecessary ERCP by pre-procedural imaging and timing of ERCP

Author

Weiland, Christina J. Sperna, Verschoor, Evelien C., Poen, Alexander C., Smeets, Xavier J. M. N., Venneman, Niels G., Bhalla, Abha, Witteman, Ben J. M., Timmerhuis, Hester C., Umans, Devica S., van Hooft, Jeanin E., Bruno, Marco J., Fockens, P., Verdonk, Robert C., Drenth, Joost P. H., van Geenen, Erwin J. M., Weiland, Christina J. Sperna, Verschoor, Evelien C., Poen, Alexander C., Smeets, Xavier J. M. N., Venneman, Niels G., Bhalla, Abha, Witteman, Ben J. M., Timmerhuis, Hester C., Umans, Devica S., van Hooft, Jeanin E., Bruno, Marco J., Fockens, P., Verdonk, Robert C., Drenth, Joost P. H., and van Geenen, Erwin J. M.

Abstract

Background: Endoscopic retrograde cholangiopancreatography (ERCP) is the procedure of choice to remove sludge/stones from the common bile duct (CBD). In a small but clinically important proportion of patients with suspected choledocholithiasis ERCP is negative. This is undesirable because of ERCP associated morbidity. We aimed to map the diagnostic pathway leading up to ERCP and evaluate ERCP outcome. Methods: We established a prospective multicenter cohort of patients with suspected CBD stones. We assessed the determinants that were associated with CBD sludge or stone detection upon ERCP. Results: We established a cohort of 707 patients with suspected CBD sludge or stones (62% female, median age 59 years). ERCP was negative for CBD sludge or stones in 155 patients (22%). Patients with positive ERCPs frequently had pre-procedural endoscopic ultrasonography (EUS) or magnetic resonance cholangiopancreatography (MRCP) imaging (44% vs. 35%; P = 0.045). The likelihood of ERCP sludge and stones detection was higher when the time interval between EUS or MRCP and ERCP was less than 2 days (odds ratio 2.35; 95% CI 1.25–4.44; P = 0.008; number needed to harm 7.7). Conclusions: Even in the current era of society guidelines and use of advanced imaging CBD sludge or stones are absent in one out of five ERCPs performed for suspected CBD stones. The proportion of unnecessary ERCPs is lower in case of pre-procedural EUS or MRCP. A shorter time interval between EUS or MRCP increases the yield of ERCP for suspected CBD stones and should, therefore, preferably be performed within 2 days before ERCP. Graphical abstract: [Figure not available: see fulltext.].

Published
2023

44. Additional file 1 of Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial

Author

Snijders, Romée J. A. L. M., Stoelinga, Anna E. C., Gevers, Tom J. G., Pape, Simon, Biewenga, Maaike, Verdonk, Robert C., de Jonge, Hendrik J. M., Vrolijk, Jan Maarten, Bakker, Sjoerd F., Vanwolleghem, Thomas, de Boer, Ynto S., Pronk, Martine A. M. C. Baven, Beuers, Ulrich H. W., van der Meer, Adriaan J., van Gerven, Nicole M. F., Sijtsma, Marijn G. M., Verwer, Bart J., Gisbertz, Ingrid A. M., Bartelink, Maartje, van den Brand, Floris F., Sebib Korkmaz, Kerem, van den Berg, Aad P., Guichelaar, Maureen M. J., Soufidi, Khalida, Levens, Amar D., van Hoek, Bart, and Drenth, Joost P. H.

Abstract

Additional file 1. Spirit checklist.

Published
2023
Full Text
View/download PDF

48. Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study

Author

Lantinga, Marten A., D’Agnolo, Hedwig M. A., Casteleijn, Niek F., de Fijter, Johan W., Meijer, Esther, Messchendorp, Annemarie L., Peters, Dorien J. M., Salih, Mahdi, Spithoven, Edwin M., Soonawala, Darius, Visser, Folkert W., Wetzels, Jack F. M., Zietse, Robert, Drenth, Joost P. H., Gansevoort, Ron T., Drenth, J. P. H., de Fijter, J. W., Gansevoort, R. T., Peters, D. J. M., Wetzels, J., Zietse, R., and DIPAK Consortium

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results